2026 Clinical Chemistry Analyzers Comparison Guide
Compare clinical chemistry analyzers from leading manufacturers with side-by-side specifications to help laboratories of all sizes evaluate throughput, workflow, assay menus, and more.
Compare clinical chemistry analyzers from leading manufacturers with side-by-side specifications to help laboratories of all sizes evaluate throughput, workflow, assay menus, and more.
The company says its US business combines automated kit manufacturing, fulfillment, sample logistics, and digital workflow technology into a single diagnostic testing platform.
As Cyclospora infections surge in the US, laboratories face increased pressure to quickly differentiate cases, with the CDC reporting 1,947 confirmed infections and 98 hospitalizations across nine states as of July 24.
Ibex Medical Analytics has received IVDR certification for its breast cancer diagnostic tools, completing regulatory approval for ER, PR, and Ki67 tests, according to a company press release.
Seegene has launched the Global Million Clinical Study to collect real-world data on the clinical utility of syndromic PCR testing for infectious diseases, aiming to inform future global diagnostic standards.
Siemens Healthineers has added CE-marked capillary blood testing for 24 assays to its Atellica core lab analyzers, enabling labs to use finger prick or heel stick samples in place of standard venipuncture.
The assay is designed to detect minimal residual disease with greater sensitivity than conventional flow cytometry.
As laboratories weigh new hemostasis investments, Sysmex experts discuss the questions that can help guide system selection.
ALZpath and Alamar Biosciences have expanded their partnership, granting Alamar commercial rights to use ALZpath’s pTau217 antibody in clinical blood tests for Alzheimer’s disease.
The noninvasive method uses paper spray and mass spectrometry to identify disease biomarkers in less than 30 seconds.
The Fleming Initiative and Cepheid have launched a 30-month study in England to compare rapid molecular and traditional culture screening for drug-resistant carbapenemase-producing Enterobacterales in hospital settings.
The funding will support regulatory certification and the commercial launch of rapid tests for Lyme disease and sexually transmitted infections.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
The automated urinalysis system integrates chemistry and microscopy to help labs manage higher testing volumes and reduce manual reviews to under 3%, according to the company.